Sygnature Discovery has launched an in vivo LPS model of inflammation to profile early- stage anti-inflammatory drugs. This will hopefully help create a better understanding of Parkinson’s Disease, Alzheimer’s Disease, multiple sclerosis, and traumatic brain injuries. The model also intends to identify new drugs.   Sygnature’s model supports early-stage anti-inflammatory in neuroinflammation, kidney and systemic inflammation. An LPS mouse model has been used as a way to inexpensively produce a...